Farallon Capital Management LLC reduced its position in shares of Allergan PLC. (NYSE:AGN) by 64.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 227,500 shares of the company’s stock after selling 420,000 shares during the quarter. Farallon Capital Management LLC owned approximately 0.07% of Allergan PLC. worth $55,303,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. Hudock Capital Group LLC raised its holdings in Allergan PLC. by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after buying an additional 2 shares during the last quarter. GWM Advisors LLC raised its holdings in Allergan PLC. by 0.4% during the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares during the last quarter. Burns J W & Co. Inc. NY raised its holdings in Allergan PLC. by 0.7% during the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares during the last quarter. Pacific Center for Financial Services raised its holdings in Allergan PLC. by 1.3% during the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after buying an additional 7 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its holdings in Allergan PLC. by 0.5% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock valued at $405,000 after buying an additional 9 shares during the last quarter. Institutional investors own 82.04% of the company’s stock.

Shares of Allergan PLC. (AGN) opened at 202.94 on Tuesday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The stock has a 50 day moving average of $217.90 and a 200-day moving average of $232.90. The stock has a market capitalization of $67.84 billion, a P/E ratio of 6.18 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $3.35 earnings per share. Analysts predict that Allergan PLC. will post $16.21 EPS for the current fiscal year.

Allergan PLC. declared that its board has initiated a stock repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.38%. Allergan PLC.’s payout ratio is currently 9.95%.

A number of equities research analysts recently commented on the stock. Royal Bank Of Canada lowered their price target on shares of Allergan PLC. from $285.00 to $277.00 and set an “outperform” rating for the company in a report on Monday, September 25th. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target for the company in a report on Monday, June 26th. BidaskClub lowered shares of Allergan PLC. from a “sell” rating to a “strong sell” rating in a report on Friday, August 25th. Mizuho reiterated a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a report on Monday, September 25th. Finally, Citigroup Inc. restated a “buy” rating and issued a $280.00 price objective on shares of Allergan PLC. in a report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $271.64.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/10/10/allergan-plc-agn-position-reduced-by-farallon-capital-management-llc.html.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.